Swing Therapeutics Closes $10.3M Series A Funding 

Swing Therapeutics$10.3M in Series B funding has been raised by, a San Francisco, CA, digital therapeutics company.

Jazz Venture Partners was the leader of the round, with participation by Asahi Kasei Corporate Ventures (Alumni Ventures), AME Cloud Ventures (Asahi Kasei Corporate Ventures), Gaingels and Kicker Ventures as well as Metrodora Ventures.

The company intends to use the funds to support the execution of the PROSPER-FM randomized clinical trial and to launch an affiliated telemedicine clinic.

Swing Therapeutics, headed by Mike Rosenbluth, is creating digital treatments and services for patients in diseases that aren’t well-served. Its primary focus is on the treatment of autoimmune conditions and chronic, overlapping pain disorders (COPCs), like fibromyalgia.

FDA Breakthrough Device Designation was granted to the company in recognition of its digital therapy for managing fibromyalgia. The company’s immediate goal is to validate and bring to market its digital therapy as an FDA-cleared prescription digital therapeutic.

PROSPER-FM studies the efficacy of two treatments for fibromyalgia. They are Digital Acceptance and Commitment Therapy(ACT), a type of cognitive behavioral therapy; and a Digital Symptom Tracker. Swing’s Digital ACT program is a daily-use digital therapeutic that includes engaging lessons and interactive exercises that help patients apply ACT principles to their unique circumstances and improve the ability to manage their condition over time. Swing’s Digital Symptom Tracker is a daily use digital therapeutic that includes common pain management approaches including monitoring daily symptoms over time and access to fibromyalgia and general health education.



Leave a Comment